Medication Management in Severe Renal Impairment

Critical Dose Adjustments

The American Journal of Kidney Diseases recommends reducing the dose of famotidine to 20mg every other day for patients with severe renal impairment (GFR <30 mL/min) to prevent CNS adverse reactions 1
For patients with GFR <30 mL/min, the dose of allopurinol should be adjusted based on creatinine clearance to prevent severe cutaneous adverse reactions, according to the Annals of the Rheumatic Diseases 2
The Kidney International guidelines suggest reassessing the indication for aspirin in patients with severe renal impairment, and considering discontinuation if used for primary prevention, due to the increased risk of bleeding 3, 4, 5

The Kidney International guidelines recommend monitoring valproic acid levels closely in patients with severe renal impairment, as renal impairment can affect protein binding and increase free drug levels 1
Olanzapine requires monitoring for adverse effects, particularly gastrointestinal effects, headache, and psychiatric symptoms, in patients with severe renal impairment, according to Praxis Medical Insights 6
Levothyroxine and vitamin D do not require dose adjustments in patients with severe renal impairment, according to the American Journal of Kidney Diseases 7

The American Journal of Kidney Diseases recommends temporarily discontinuing potentially nephrotoxic drugs during acute illness, and monitoring for signs of nephrotoxicity, in patients with severe renal impairment 7, 8
Monitoring for drug accumulation and surveillance for CNS effects, such as confusion and delirium, is crucial in patients with severe renal impairment, according to Kidney International 1, 8
Renal function should be monitored every 3 months, with more frequent monitoring warranted in patients with multiple medications requiring renal dose adjustment, according to the American Journal of Kidney Diseases 7, 8

The American Journal of Kidney Diseases advises against continuing famotidine at current BID dosing in patients with severe renal impairment, due to the increased risk of CNS toxicity 7
NSAIDs and COX-2 inhibitors are contraindicated in patients with GFR <30 mL/min, due to the risk of nephrotoxicity, according to the American Journal of Kidney Diseases 7
Metformin is contraindicated in patients with GFR <30 mL/min, and aminoglycosides, gadolinium contrast, and high-dose penicillins should be avoided, according to the American Journal of Kidney Diseases and the American Journal of Respiratory and Critical Care Medicine 7, 8, 9